Animal Health: Local Problem - Global Issue
•Télécharger en tant que PPT, PDF•
2 j'aime•621 vues
Great Week Agri-Tech at the Milan Expo 2015. Animal Sciences Across Borders - 7th July 2015 Presentation by GALVmed CEO, Peter Jeffries. Addressing animal health challenges in developing countries in Africa can prevent local impacts becoming a reservoir for global problems. This session will address issues and provide answers focusing on the need for affordable solutions on the ground. For more information on Great Week Agri-Tech visit: https://www.events.ukti.gov.uk/great-week-agri-tech/ For more information on GALVmed visit: www.galvmed.org
Recommandé
Recommandé
Contenu connexe
Tendances
Tendances (19)
Similaire à Animal Health: Local Problem - Global Issue
Similaire à Animal Health: Local Problem - Global Issue (20)
Dernier
Dernier (20)
Animal Health: Local Problem - Global Issue
- 2. 2 Animal Health: Local Problem – Global Issue Peter Jeffries Chief Executive GALVmed
- 3. Global Alliance for Livestock Veterinary Medicines
- 4. Livestock – Vital Assets for 900 million people Slide 4
- 5. Macro View: major unmet needs Slide 5 Global Livestock Density
- 6. Micro View: swift return on investment Slide 6 Return on investment to Farmer >10 x investment
- 7. GALVmed: what do we do? • Product development – Private sector approach development of products against neglected diseases • Market Creation – Repairing the missing links in the value chain » Awareness economic impact of livestock disease » Cold chain maintenance » Training of vaccinators » Sustainable business models » Scale & Impact • Policy – Partnering to ensure livestock & animal health policy is aligned with practical need To edit click View>Header and Footer 7
- 8. Slide 8 Disease Targets Cattle • East Coast Fever • Contagious Bovine Pleuropneumonia • Trypanosomosis Sheep and goats • Peste des petits ruminants • Contagious caprine pleuropneumonia • Sheep & goat pox Pigs • Porcine cysticercosis • African swine fever Poultry • Newcastle disease Multi-species • Rift Valley fever • Brucellosis
- 9. Partnerships Slide 9 Product Development Market Development Research Partners Farmer GALVmed Policy Support Manufacturer Monitoring & Evaluation Funded by UK Government Department for International Development & the Bill & Melinda Gates Foundation
- 10. To edit click View>Header and Footer 10 Innovation at Field Level A novel partnership for sustainable delivery of animal health inputs at village level in India
- 11. Households Reached: South Asia Newcastle Disease Vaccination Projects 11 Scale up for Impact
- 13. Newcastle disease virus Lasota strain per dose 20 Product Features Potency >1x106 EID50 of Dose Size 50, 100 & 200 doses Storage 20C to 80C (fridge) Stability • 18 months at 20C to 80C • 10 days at 370C • 7 days at 400C
- 14. Newcastle disease virus Lasota strain per dose 20 Product Features Potency >1x106 EID50 of Dose Size 50, 100 & 200 doses Storage 20C to 80C (fridge) Stability • 18 months at 20C to 80C • 10 days at 370C • 7 days at 400C
- 15. Chhattisgarh Jharkhand Orissa Covers 3 states in India Dedicated sales team of 21 people Hire and train over 2000 individuals as ‘vaccinators’ Invest in infrastructure for development & distribution of vaccines & health products Create a sustainable distribution network linked with Hester’s current network Periodic sero-monitoring for impact measurement 23 Target: the Poorest States in India
- 16. 22 Sheep and Goat Package Dewormer PPR Vaccine Goatpox vaccine Brucellosis vaccine Cattle Package Dewormer Brucellosis vaccine Poultry Package Thermostable Newcastle Disease vaccine Dewormer While we’re there…
- 17. Basic Rationale: Improved Livelihoods Slide 17 Average value of live chicken at market: $4.50 Cost of thermostable Newcastle Disease vaccine: $0.02 80% mortality
- 18. Before After Monthly income from poultry sales (INR) Monthly income from poultry sales (INR) Annualspend(INR) Spend on Livestock Health Products vs Income from Poultry Sales 18 It makes financial sense
- 20. Newcastle Disease Vaccine & Child Nutrition “In the past, many of our chickens were killed by disease, leaving only a handful of pullets and hens… Since the birds were vaccinated, none have died...Our flock has grown again and we now have lots of birds. We have just sold six chickens and made a whopping profit… The income means that we can afford to educate our children and buy them proper food and decent clothes.” Slide 20 Mrs Padma Soren,Orissa, India
- 21. Stake Holder responsibilities GALVme d Hester Partners 31 • Govt. Organizations • Consultants • Local NGO’s • CAHW • SHG • Media • Product • Distribution network • Recruitment • Training • Technology • Funding • Liaising • Monitoring
- 22. Measurable Benefit Better health protection for animals Higher disposable household incomes Empowerment women to 32
- 23. 36m 56m 100m 21 Projected doses per year Product Year 1 Year 2 Year 3 Thermostable ND Vaccine Meaningful scale and Impact
- 24. Expected Benefit = Sustainability 17.70 46.70 70.20 2.4 2.6 3.3 33 Parameters Year 1 Year 2 Year 3 Hester Sales (INR m) Average birds/ household 5 7 10 Number of Households (m)
- 25. Plus ça change… Slide 25
Notes de l'éditeur
- GALVmed’s starting point begins, importantly, with what people in poverty have – livestock. For how many people? For around one billion. Assets that people rely upon for milk, eggs and protein. Livestock provide income for basic health care and access to education, manure for fertiliser, traction and are often central in cultural and religious festivals. A chicken has a value ranging from USD $4 -$7; a goat USD $70 - $120 and a beef animal or dairy cow is worth USD$500-$900. For people living on $2 per day – and half the world does – livestock are extremely valuable assets.
- Livestock are frequently destroyed by livestock disease or the productivity of the animals reduced, impacting the lives of individuals, families and communities. The burden of disease and so our efforts are focused on sub-Saharan Africa and S.Asia. Here in red - in excess of 15tons of livestock per square kilometre. The effects of the indirect impact of livestock disease are often overlooked and extremely important because that is where people stop investing in livestock – in proper feed, housing, husbandry & animal health.
- Effective animal health products, in particular vaccines have phenomenal return on investment for small-scale farmers. For a tiny outlay, the return is off the scale. It is quite common for the small-scale farmer to receive a return on investment with a livestock vaccine of around three thousand percent. With such need in the world, it’s vital that these valuable agricultural inputs – the vaccines - can be made available to the millions of people who desperately need them
- We work on 13 critical neglected diseases across all these species considered to be the key diseases impacting people living in poverty in developing countries. These include zoonotic diseases that pass from animals to humans such as Rift Valley Fever Committees of international experts bolster GALVmed’s in-house expertise by advising on which diseases are most impactful to people living in poverty.
- We need to work from the laboratory and the negotiating table right through to ensuring that the product gets into the animal. Product Development is required because products often don’t exist. If it can be made, we then need to be able to get it out. To do so at scale, we need a market serving it driven by the power of supply and demand. This requires a groundswell of awareness amongst livestock keepers – an awareness amongst potential vaccinators of the income they can make and a realisation of the scale of the market at Distributor and Manufacturer level. Behind the scenes, invaluable policy work is required to address policy issues. A fundamental tenet of our work is that products be registered in the nation where they are to be used so that they are regulated there and can be commercialised. Finally, there’s a need for a cohesive framework to bring everything together and this is GALVmed’s role.
- A large commercial vaccine manufacturer, Hester, with whom we are working intend to reach 3 and a half million households in the next few years with the thermotolerant Newcastle Disease vaccine.
- WHO – GMP, Good Laboratory Practices (GLP), ISO 9001:2008, ISO 14001:2004, OHSAS 18001:2007, Government approved R&D Unit
- We are able to demonstrate to the private sector the formation of a new and very significant market segment The graph here shows subsequent investment in livestock health products by people living in poverty before and after vaccination. When they see that they earn more – there is a transformation in mindset & practice - they invest more in livestock health products. Our commercial partners recognise the commercial viability and so an effective product is created and made widely and affordably available. (Monthly income in Indian Rupees is shown along the horizontal axis and annual spend on livestock health products in the vertical axis).
- Better health for animals, higher disposable income, empowerment of women, better nutrition and better livelihoods
- This collaboration he collaboration has a very real and personal effect on the lives of individuals, families and communities. Being able to vaccinate and protect her chickens, enables Padma Soren here from one of India poorest states to feed and educate her children. All of our work is dedicated to protecting livestock – improving human lives.
- Thank you! I welcome any questions you might have.